Salim A S
University Department of Surgery, Medical City, Baghdad, Iraq.
Pharmacology. 1992;45(6):307-18. doi: 10.1159/000139016.
This double-blind randomised study investigated the role of sulphydryl-containing agents in the management of recurrent attacks of ulcerative colitis. To this end, DL-cysteine (200 mg 4 times daily) and DL-methionine-methyl sulphonium chloride (MMSC, 500 mg 4 times daily) were administered orally. Patients with recurrent attacks of moderate proctosigmoidal ulcerative colitis, despite prophylaxis by oral sulphasalazine (2 g daily), were given prednisolone by mouth, 10 mg four times a day, sulphasalazine by mouth, 500 mg four times a day, and morning and evening retention enema (Predsol 20 mg) alone or with cysteine or MMSC. After 2 weeks of treatment with sulphasalazine and prednisolone, 51% of patients (n = 45) were symptom free. Addition of cysteine (n = 46) or MMSC (n = 47) to this regimen controlled the symptoms within 2 weeks in 85% of patients (p < 0.01). During 12 months of prophylactic treatment, 5% of patients (n = 42) receiving sulphasalazine (2 g daily) and cysteine and 5% of patients (n = 41) taking sulphasalazine (2 g daily) and MMSC relapsed, relative to 27% of cases with sulphasalazine (2 g daily) alone (p < 0.01). These results demonstrate that sulphydryl-containing agents play a key role in the treatment of and protection against ulcerative colitis.
这项双盲随机研究调查了含巯基药物在溃疡性结肠炎复发治疗中的作用。为此，口服给予DL-半胱氨酸（每日4次，每次200毫克）和DL-蛋氨酸甲基磺酰氯（MMSC，每日4次，每次500毫克）。尽管口服柳氮磺胺吡啶（每日2克）进行预防，但仍有中度直肠乙状结肠溃疡性结肠炎复发的患者，口服泼尼松龙，每日4次，每次10毫克，口服柳氮磺胺吡啶，每日4次，每次500毫克，并单独或与半胱氨酸或MMSC一起早晚进行保留灌肠（Predsol 20毫克）。在用柳氮磺胺吡啶和泼尼松龙治疗2周后，51%的患者（n = 45）无症状。在此治疗方案中添加半胱氨酸（n = 46）或MMSC（n = 47）后，85%的患者在2周内症状得到控制（p < 0.01）。在12个月的预防性治疗期间，接受柳氮磺胺吡啶（每日2克）和半胱氨酸的患者中有5%（n = 42）复发，服用柳氮磺胺吡啶（每日2克）和MMSC的患者中有5%（n = 41）复发，而单独使用柳氮磺胺吡啶（每日2克）的患者复发率为27%（p < 0.01）。这些结果表明，含巯基药物在溃疡性结肠炎的治疗和预防中起关键作用。
